Growth & profitability
- Revenue has grown 128.5% per year over the past 5 years.
Financial health
- Operating income covered interest expense -1.5× in the latest year.
MIRM Financials Mirum Pharmaceuticals, Inc.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $521M | -$23M | 0.0% | -4.2% | -7.4% | -2.8% | $55M | — | $297M |
| 2024 | $337M | -$88M | 0.0% | -26.0% | -39.0% | -13.1% | $9M | — | $223M |
| 2023 | $186M | -$163M | 0.0% | -58.6% | -65.7% | -25.3% | -$71M | — | $286M |
| 2022 | $77M | -$136M | 0.0% | -170.3% | -95.5% | -38.4% | -$120M | — | $28M |
| 2021 | $19M | -$84M | 0.0% | -906.1% | -69.9% | -28.5% | -$133M | — | $31M |
| 2020 | — | -$103M | — | — | -60.0% | -42.9% | -$89M | — | $142M |
| 2019 | — | -$53M | — | — | -40.3% | -35.8% | -$40M | — | $12M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $176M | -$67M | 0.0% | -24.1% | 645.0% | -6.4% | -$44M | — | $331M |
| Mar '26 | $160M | -$790M | 0.0% | -493.8% | -325.8% | -88.7% | -$229M | — | $325M |
| Dec '25 | $149M | -$6M | 0.0% | -3.1% | -1.8% | -0.7% | $5M | — | $297M |
| Sep '25 | $133M | $3M | 0.0% | 2.0% | 1.0% | 0.4% | $39M | — | $282M |
| Jun '25 | $128M | -$6M | 0.0% | -3.9% | -2.3% | -0.8% | $12M | — | $228M |
| Mar '25 | $112M | -$15M | 0.0% | -13.6% | -6.3% | -2.1% | -$2M | — | $212M |
| Dec '24 | $99M | -$24M | 0.0% | -24.4% | -10.5% | -3.5% | -$5M | — | $223M |
| Sep '24 | $90M | -$14M | 0.0% | -14.0% | -6.1% | -2.1% | $4M | — | $223M |
| Jun '24 | $78M | -$25M | 0.0% | -31.1% | -10.8% | -3.7% | -$5M | — | $233M |
| Mar '24 | $69M | -$25M | 0.0% | -38.2% | -10.8% | -3.9% | $15M | — | $303M |
| Dec '23 | $70M | -$36M | 0.0% | -46.8% | -14.3% | -5.5% | -$17M | — | $286M |
| Sep '23 | $48M | -$24M | 0.0% | -52.7% | -8.8% | -3.6% | -$18M | — | $303M |
| Jun '23 | $37M | -$74M | 0.0% | -64.7% | -94.2% | -16.7% | -$17M | — | $297M |
| Mar '23 | $32M | -$30M | 0.0% | -85.9% | -21.3% | -9.0% | -$19M | — | $49M |
| Dec '22 | $28M | -$36M | 0.0% | -122.4% | -25.6% | -10.3% | -$35M | — | $28M |
| Sep '22 | $19M | -$36M | 0.0% | -175.1% | -21.1% | -9.8% | -$26M | — | $36M |
| Jun '22 | $17M | -$27M | 0.0% | -179.8% | -24.3% | -9.1% | -$20M | — | $55M |
| Mar '22 | $13M | -$37M | 0.0% | -253.9% | -33.6% | -13.2% | -$40M | — | $46M |
| Dec '21 | $3M | $58M | 0.0% | -1452.4% | 47.9% | 19.5% | -$33M | — | $31M |
| Sep '21 | $5M | -$47M | 0.0% | -856.5% | -83.5% | -20.0% | -$34M | — | $56M |
Valuation over time
How the market has priced MIRM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 20.2× (Mar '23) to 12.5× (Sep '26).
P/S
Frequently asked questions
Is MIRM growing its revenue and profit?
Over the past 5 years, Mirum Pharmaceuticals, Inc.'s revenue has grown 128.5% per year. These are computed facts, not advice.
How much debt does MIRM have?
As of FY2025, Mirum Pharmaceuticals, Inc. reported — of total debt against $297M of cash; operating income covered interest expense -1.5×.
What is MIRM's profit margin?
In FY2025, gross margin was —, operating margin -4.2%, and net margin -4.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.